Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology 

September 16, 2020 1:14 AM UTC

NIH launches Accelerating Medicines Partnership for schizophrenia
NIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative to find biomarkers that identify individuals at risk for developing schizophrenia, predict the likelihood of disease progression and point to therapeutic targets. Companies involved include Boehringer Ingelheim GmbH, Otsuka Holdings Co. Ltd. (Tokyo:4578) and the Janssen Research & Development unit of Johnson & Johnson (NYSE:JNJ). External partners will contribute $16.5 million over five years, and NIH’s National Institute of Mental Health (NIMH) plans to contribute $82.5 million over the same period. AMP SCZ is NIH’s fifth AMP initiative, and the first focused on a neurological disease.

Boehringer, Click partner for digital therapeutic for schizophrenia
Boehringer and Click Therapeutics Inc. are partnering to develop and commercialize CT-155, a prescription-based mobile application based on the principles of cognitive behavioral therapy. The German pharma will receive exclusive global rights to CT-155; Click will receive an undisclosed upfront payment and development funding, and is eligible to receive clinical, regulatory and commercial milestones for a total deal value of more than $500 million, plus tiered royalties...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article